


# CLAIMS


1. A compound of formula (I) which is 4-(8-methoxy-1-(1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole



(I)

or a salt thereof.


2. A compound of formula (IA) according to claim 1 which is 4-(8-methoxy-1-((R)-1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole



(IA)

or a salt thereof.

3. A compound of formula (IB) according to claim 1 which is 4-(8-methoxy-1-((S)-1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole



(IB)

or a salt thereof.

4. A compound according to any one of claims 1 – 3 or a pharmaceutically acceptable salt thereof.

5. A compound according to claim 4 in the form of a free base.

6. A compound according to claim 4 in the form of a methanesulfonate salt.

5 57. A pharmaceutical composition which comprises a compound or a pharmaceutically acceptable salt thereof as defined in claim 4 and one or more pharmaceutically acceptable carriers, diluents or excipients.

68. A combination pharmaceutical product comprising a compound or a pharmaceutically acceptable salt thereof as defined in claim 4 together with one or more other  
10 therapeutically active agents.

79. A compound or a pharmaceutically acceptable salt thereof as defined in claim 4 for use in therapy.

810. A compound or a pharmaceutically acceptable salt thereof as defined in claim 4 for use in the treatment of diseases or conditions for which a bromodomain inhibitor is  
15 indicated.

911. A compound for use according to claim 810, wherein the disease or condition is a chronic autoimmune and/or inflammatory condition.

1012. A compound for use according to claim 810, wherein the disease or condition is cancer.

20 1113. A compound for use according to claim 912 in which the cancer is selected from hematological, epithelial including lung, breast and colon carcinomas, midline carcinomas, mesenchymal, hepatic, renal and neurological tumours.

1214. The use of a compound or a pharmaceutically acceptable salt thereof as defined in claim 4 in the manufacture of a medicament for the treatment of cancer or a chronic  
25 autoimmune and/or inflammatory condition.

1315. The use of a compound or a pharmaceutically acceptable salt thereof as defined in claim 4 in the manufacture of a medicament for the treatment of cancer selected from hematological, epithelial including lung, breast and colon carcinomas, midline carcinomas, mesenchymal, hepatic, renal and neurological tumours.